Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression

Chen, L. N.; Wang, Y.; L., D.; Chen, Yingyang

doi:10.1007/s10495-005-3134-y

Cited by 58 publications

(51 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data suggest that loss or reduction of PDCD5 expression may also be a prognostic factor for serous cystadenocarcinoma. It has been reported that adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo, and blocking PDCD5 action by anti-PDCD5 antibody is able to suppress apoptosis induced by etoposide and knocking down its expression by PDCD5-specific siRNA attenuates cell apoptosis induced by Bax overexpression (4,20). Our preliminary result also showed overexpression of PDCD5 in the glioma cells can enhance cisplatin induced apoptosis (unpublished data), suggesting PDCD5 may prolong survival time of patients with cancers by enhancing apoptosis of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas

Zhang

Wang²,

Song³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Programmed cell death 5 (PDCD5) is a novel apoptosis-promoting protein. Although the decreased expression of PDCD5 has been recently found in a few types of human tumors, the status and significance of PDCD5 in ovarian cancer has not been evaluated. In the present study, we detected PDCD5 expression in 20 normal human ovaries and 26 serous cystadenomas and 41 serous cystadenocarcinomas by RT-PCR, Western blotting and immunohistochemistry, and analyzed the relationship between PDCD5 expression and clinicopathological data or patient survival. PDCD5 was expressed in all normal ovaries and serous cystadenomas, 80% (16/20) of normal ovarian tissues and 76.9% (20/26) of serous cystadenomas with moderate or strong PDCD5 protein expression. In contrast, 22% (9/41) of serous cystadenocarcinomas had no detectable PDCD5 protein expression and 46.3% (19/41) exhibited weak PDCD5 expression. The overall expression of PDCD5 in serous cystadenocarcinoma was significantly lower compared with normal ovarian tissues or serous cystadenomas (p<0.01). Furthermore, lost or decreased PDCD5 expression in serous cystadenocarcinomas was associated significantly with FIGO stage (p<0.05) and poorer diseasespecific survival of patients (p<0.05). In conclusion, our data suggest that lost or reduced PDCD5 expression may contribute to the pathogenesis of human serous cystadenocarcinomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas

Zhang

Wang²,

Song³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…The open reading frame of PDCD5 encodes a 125-aa protein that is highly conserved ranging from yeast to human (4). PDCD5 is ubiquitously expressed in different tissues and involved in the regulation of apoptosis in different cell types (4)(5)(6)(7)(8). The apoptotic potential of PDCD5 may be partially resulted from its phosphorylation at serine 118 by CK2, which is required for the nuclear translocation of PDCD5 in response to genotoxic stress (9,10).…”

Section: Introductionmentioning

confidence: 99%

PDCD5 regulates cell proliferation, cell cycle progression and apoptosi

Hong-xin

Wang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Programmed cell death (PDCD)5 is cloned from human leukemia cell line TF-1. PDCD5 is one of the members of the programmed cell death protein family that is frequently involved in tumor growth and apoptosis. To investigate the molecular and cellular functions of PDCD5, the present study established a PDCD5 stably overexpressing A431 cell line and examined the role of PDCD5 in cell proliferation, cell cycle progression and apoptosis. The data demonstrated that overexpression of PDCD5 significantly inhibited cell proliferation, induced cell cycle arrest at G2/M phase and apoptosis in A431 cells. The expression profiles of certain key regulators of these cellular events were further investigated, including P53, B cell lymphoma (BCL)-2, BCL-2 associated X protein (BAX) and caspase (CASP)3. The data demonstrated that at the transcript and protein levels, P53, BAX and CASP3 were all upregulated in the PDCD5 stably overexpressing A431 cells whereas BCL-2 was downregulated, indicating that PDCD5 acts as an important upstream regulator of P53, BCL-2, BAX and CASP3. The data suggest that PDCD5 regulates cell proliferation, cell cycle progression and apoptosis in A431 cells. PDCD5 may be a novel tumor suppressor gene, and may be potentially used for cancer treatment in the future.

show abstract

“…Downregulation of PDCD5 expression has been found in various malignancies, such as breast cancer [8] , hepatocellular carcinoma [9] , cervical cancer [10] , gastric cancer [11] , lung cancer [12] , acute and chronic myelogenous leukemia [13][14][15] , astrocytic gliomas [16] , prostate cancer [17] and papillary thyroid carcinoma (PTC) [3] . Inhibition of PDCD5 expression by siRNA could inhibit cell apoptosis [19] , and the sensitivity of HeLa cells to apoptosis induced by etoposide is reduced by in situ electroporation of the anti-PDCD5 monoclonal antibody [20] . Overexpression of PDCD5 facilitates apoptosis triggered by certain stimuli in cancer cell lines such as HeLa and MGC-803 [1] .…”

Section: Discussionmentioning

confidence: 99%

Determination of PDCD5 in peripheral blood serum of cancer patients

Wang

Zhang

2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: Programmed cell death 5 (PDCD5) is an apoptosis related gene and plays an important role in the pathogenesis and development of cancer. Whether PDCD5 is present in peripheral blood serum has not been reported. The aim of this study is to determine the contents of PDCD5 protein in peripheral blood serum of cancer patients, as well as normal subjects.Methods: ELISA was used to detect the serum PDCD5 concentrations in 100 normal persons, 83 patients with breast cancer, 74 patients with gastrointestinal tract cancer and 41 patients with lung cancer. The results were statistically analyzed and discussed.Results: PDCD5 could be detected in peripheral blood serum in both normal subjects and cancer patients. The serum PDCD5 contents in normal persons ranged from 3.8 to 6.1 ng/ml with a median of 4.70±0.68 ng/ml. For cancer patients the PDCD5 levels were 4.59±0.90, 4.79±1.14 and 10.43±22.34 ng/ml for breast cancer, gastrointestinal cancer and lung cancer patients respectively. There was no statistically significant difference between the serum PDCD5 concentrations of normal persons and cancer patients.Conclusion: PDCD5 is present in peripheral blood. The PDCD5 levels in cancer patients are not statistically different from that of normal persons, though decreased expression of PDCD5 in malignant tissues has been found.

show abstract

Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression

Cited by 58 publications

References 35 publications

Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas

Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas

PDCD5 regulates cell proliferation, cell cycle progression and apoptosi

Determination of PDCD5 in peripheral blood serum of cancer patients

Contact Info

Product

Resources

About